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Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are
perceived to have less toxicity compared with the available cytotoxic agents. While various immune-based
strategies can elicit anti-tumour responses, DNA vaccines present increased efficacy, inducing both humoural and
cellular immunity. This immune activation has been proven effective in animal models and initial clinical trials are
encouraging. However, to validate the role of DNA vaccination in currently available PCa management paradigms,
strong clinical evidence is still lacking. This article provides an overview of the basic principles of DNA vaccines and
aims to provide a summary of preclinical and clinical trials outlining the benefits of this immunotherapy in the
management of PCa.Introduction
Prostate cancer (PCa) is a major urological problem
associated with significant morbidity and mortality [1].
Although the majority of PCa cases are localised to the
prostate, nearly one-third of newly diagnosed patients
have advanced or metastatic disease [2]. Radical prosta-
tectomy and radical radiotherapy are potentially curative
treatment options for localised PCa. For those with lo-
cally advanced or metastatic disease, the initial systemic
therapy is androgen deprivation therapy. Unfortunately,
nearly all patients in this group eventually progress to
castration resistant PCa (CRPC). For CRPC, docetaxel
based chemotherapy is used as first-line. However, this
only provides modest survival benefit (2.4 months) and
is associated with significant side effects [3]. Insights
into the regulation of immune responses in malignancies
have facilitated the emergence of novel immune-based
strategies. PCa is an attractive target for vaccination due
to its slow growth which can allow sufficient time for
immune activation [4]. Additionally, the identification of
prostate tumour associated antigens (that are recognised
by T cells) has created the opportunity to develop novel
immune based therapeutic approaches. Several tumour
associated antigens have been identified, including pros-
tate specific antigen (PSA), prostatic acid phosphatase* Correspondence: m.tangney@ucc.ie
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reproduction in any medium, provided the or(PAP), prostate stem cell antigen (PSCA) and prostate
specific membrane antigen (PSMA) [5]. These antigens
are largely prostate specific and their expression is
strongly upregulated in PCa, both locally and at meta-
static sites [6,7]. This makes these antigens a viable tar-
get of active immunotherapy and can be used as DNA
vaccines. Furthermore, PSA-specific cellular immune
responses have been detected in some PCa patients and
in normal individuals, suggesting that tolerance towards
this antigen may be broken [8]. These observations led
to development of a variety of vaccines for PCa in pre-
clinical and clinical trials. These vaccines can be broadly
classified as whole cell vaccines [9], protein/peptide
based vaccines [10,11], viral vector based vaccines [12],
dendritic cell vaccines [13] and naked DNA vaccines
[14,15].
Like other forms of targeted therapy, cancer vaccines
hold the promise of achieving cancer control without in-
ducing overt toxicity. The focus of extensive research for
PCa vaccine has led to the approval of the first thera-
peutic vaccine (sipuleucel-T) by the FDA [16]. The
sipuleucel-T is an autologous antigen presenting cell
(APC) based and antigen-targeted immunotherapeutic
innovation for men with CRPC [16]. The success story
of the sipuleucel-T encouraged researchers to explore
other agents/strategies to activate immune system
against PCa. Gene therapy (including DNA vaccines) is a
realistic prospect for the treatment of prostate and other
cancers, and involves the delivery of genetic informationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proteins. A DNA vaccine consists of tumour specific/
associated antigen and additional immune-stimulatory
factors cloned into a bacterial plasmid downstream of an
appropriate eukaryotic promoter for strong and stable
expression. DNA vaccination can induce effective anti-
tumour responses against various malignant cells and
provides an attractive strategy for the management of
PCa [17-19].
Why DNA vaccines?
DNA immunisation can efficiently stimulate humoural
and cellular immune responses to protein antigens. This
strategy has been used successfully for infectious dis-
eases [20] and potentially can be applied for malignant
conditions. There are several advantages associated with
DNA vaccines:
 Various groups have demonstrated tumour
protection using DNA immunisations in several pre-
clinical cancer models [21-26].
 Gene sequences can be manipulated easily to
provide multiple potential epitopes that stimulate
both humoural and cellular immunity [22,27-29].
 DNA vaccines generally skew the immune system
toward the desired T-helper1 (Th1) response. This is
most likely because plasmid DNA contains
unmethylated CpG motifs, which have been shown
to be a very potent immunological adjuvant [30,31].
 DNA immunisation is safe in humans [14,32] and
can induce antigen-specific immune responses
[30,33].




For malignant diseases, immunological therapies fall into
two general categories; active and passive immunother-
apy. Active immunotherapy attempts to directly elicit
tumour-specific host immune responses that control or
eradicate tumours. In contrast, passive immunotherapy
involves the direct administration of effector molecules,
such as cytokines or monoclonal antibodies. These
molecules promote the development of anti-tumour
responses, directly killing tumour cells, or inhibit cell in-
vasion and angiogenesis [35]. The nature of the host im-
mune response that can control tumour growth has
been the focus of many studies. With few exceptions,
the most effective anti-tumour immune responses in
animal models have depended on the efficient gener-
ation of Th1 cell immunity, characterised by strong cyto-
toxic T lymphocyte (CTL) responses [27,28,36]. This is
supported by observations in humans that progressivedisease is characterised by an anti-tumour T-cell re-
sponse [37] as well as by clinical evidence that Th1 T
cells can control and eliminate metastatic disease
[28,38]. B cell effector functions are another important
component of this anti-tumour immune response (see
below).
Process of DNA vaccination
A typical DNA vaccine consists of a transgene that
encodes the sequence of a target protein (e.g. PSA,
PSMA etc.) under the control of a eukaryotic promoter.
Various modalities exist for delivering such DNA to ap-
propriate cells (see below). After uptake of the plasmid,
the target protein is produced within the cell and pro-
cessed into small antigenic peptides by host proteases.
The peptides then enter the lumen of the endoplasmic
reticulum (E.R.) by membrane-associated transporters.
In the E.R., the peptides bind to Major Histocompatabil-
ity Complex I (MHC I) molecules. These peptides are
presented on the cell surface in the context of MHC I.
Subsequently CD8+ CTL are stimulated resulting in cell-
mediated immunity. CTLs cause tumour destruction
through both cytolysis of malignant cells and non-
cytolysis mechanisms such as cytokines production.
The foreign protein on the plasmid can also be pre-
sented by MHC II pathway by APC which elicit CD4+
helper T cells responses. These CD4+ T cells can recognise
the peptides generated from the exogenous proteins that
were endocytosed or phagocytosed by APC, then
degraded to peptide fragments and loaded onto MHC II
molecules. Depending on the type of CD4+ T cell that
binds to the complex, B cells are activated and antibody
production is stimulated. This is the same manner in
which traditional vaccines work [39]. Vaccine-elicited anti-
bodies can mediate direct effects against tumour cells by
fixing complement or facilitating antibody-dependent cel-
lular cytotoxicity. Overall, stimulation of both the T and B
cell arms of the immune system mediates synergies and
creates a large pool of effectors cells to control tumour
growth and induce generation of memory cells (Figure 1).
Methods of DNA delivery
Transfection of the host cell with the plasmid is a limit-
ing step for a successful DNA vaccination. Most com-
monly, the DNA vaccines are given by intramuscular
(i.m.) or intradermal (i.d) injections. To facilitate the gene
delivery, various methods have been reported including
viral, liposomal, bacterial, ultrasound and electroporation
(EP), as well as approaches involving ex vivo transfection/
transduction of cells (e.g. APC) [40]. To avoid safety
issues such as immune response and cytotoxicity asso-
ciated with viruses and liposomal transfection, physical
methods (ultrasound, EP etc.) have been widely used for
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Figure 1 Mechanism of action of DNA vaccine after intra muscular (i.m.) plasmid delivery. Transfected muscle cells produce the antigen
expressed on the plasmid. This antigen is expressed to cell surface with MHC I and presented to cytotoxic CD8+ T cells (Cell mediated Immunity).
Antigen is also excreted by the muscle, which is phagocytosed by the professional Antigen Presenting Cells (APC), usually Dendritic cells. A small
proportion of DNA vaccine is also taken up directly by APC and the encoded antigen can then be processed and presented endogenously
(Humoural Immunity).
Ahmad et al. Genetic Vaccines and Therapy 2012, 10:9 Page 3 of 9
http://www.gvt-journal.com/content/10/1/9emerged as a potent method for DNA vaccine delivery
and significantly improves transfection efficiency of naked
plasmid DNA [41]. EP driven DNA vaccination increases
antigen expression by increasing transfection efficiency
(Figure 2) and is accompanied by local tissue injury and
inflammation [42]. Hence, the outcomes of EP mediated
vaccination are dramatic enhancement of humoural and
cellular immunity [43,44].
Preclinical studies
Numerous preclinical studies have been carried out to
demonstrate the efficacy of DNA vaccines in animal
models of PCa. The following vital issues regarding suc-
cessful vaccines were addressed in these preclinical trials;
– Induction of immune response/type of immune
activation
– Optimisation of vaccine dose/schedule
– Mode of delivery
– Breaking tolerance to self-antigen
– Systemic responses /control of metastatic disease
– Need for adjuvant to vaccines
– Transferable immunity
Prostate-specific antigens examined
Roos et al. [45] showed for the first time that a PSA
DNA vaccine can induce anti-tumour immunity in vivo.They investigated a DNA vaccination strategy to immun-
ise mice by inducing PSA-specific cellular responses. A
plasmid expressing PSA, alone or in combination with
plasmids coding for granulocyte-macrophage colony-
stimulating factor (GM-CSF) and/or IL-2, were used. It
was found that the DNA vaccine induced PSA-specific
cytotoxic T lymphocytes and when co-injected with
GM-CSF and IL-2 it can protect mice against a PSA-
expressing tumour challenge. This demonstrated that
immunisation with a PSA DNA vaccine can evoke PSA-
specific cellular immunity. The ability of the DNA vac-
cine to stimulate both humoural and cellular immune
responses was demonstrated by Kim et al. [24]. They
observed a strong and persistent antibody response
against PSA for at least 180 days following immunisa-
tion. Additionally, significant T helper cell proliferation
was also detected against PSA. Furthermore, immunisa-
tion with PSA plasmid induced CD8+ T cell-restricted
cytotoxic T cell response against tumour cell expressing
PSA.
PSMA is a 750 amino acid surface protein expressed
primarily in prostate epithelium, Most reported antibodies
to PSMA apparently recognise epitopes in the residue
43–570 region of the extra cellular domain, and upon
binding are rapidly removed from the cell surface by in-
ternalisation. This would potentially limit their ability to
mediate Fc-dependent cytotoxicity. Kuratsukuri et al.
a b
c d
Figure 2 Schematic representation of Electroporation mediated transfection. a) Intra-muscular plasmid injection. b) Electroporation.
c) Transient increased permeability of cell membrane (yellow arrows) results in transfer of the plasmid into the cell. d) Cell membrane return to
resting membrane (red arrow) and gene transfection results in production of mRNA and hence specific protein.
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the extra cellular domain of PSMA. Their results sug-
gested that vaccination with plasmid expressing extra cel-
lular domain of PSMA induced adaptive humoural
activity, which was directed against the extracellular re-
gion of human PSMA and can significantly inhibit human
PCa growth in athymic mice.
Viral delivery of vaccine antigens is an active research
area. However, a potential difficulty with viral-based
immunisations is that immune responses elicited to the
viral vector might limit the possibility of multiple
immunisations. Johnson et al. [48] investigated a DNA
vaccine encoding PAP, to elicit antigen-specific CD8+ T
cell immune responses. In their study, Lewis rats were
immunised with either a plasmid DNA-based (pTVG-
HP) or Vaccinia-based (VV-HP) vaccine each encoding
human PAP (hPAP). They observed Th1-biased im-
mune response (as indicated by proliferating PAP-
specific CD4+/CD8+ cells and IFN- γ production) in
rats immunised with a DNA vaccine encoding hPAP.
Immunisation with Vaccinia virus (encoding hPAP)
could not induce PAP-specific response, unless boosted
with a heterologous vaccination scheme. Furthermore,
they also established that multiple immunisations with
a DNA vaccine encoding the rat PAP homologue
(pTVG-RP) could overcome peripheral self-tolerance
against rat PAP (rPAP) and generate a Th1-biased anti-
gen-specific CD4+ and CD8+ T cell response. In separ-
ate experiments, this DNA vaccine has not shownsignificant toxicities in terms of animal weights, histo-
pathology, haematological changes, or changes in serum
chemistries [49]. The vaccine was found to be effective
in eliciting PAP-specific CD4+ and CD8+ T cells, pre-
dominantly Th1 in type, in all immunised animals at all
doses and numbers of immunisations. PAP-specific IgG
were detected in a dose-dependent fashion, with titres
increasing after multiple immunisations.
Optimisation of DNA vaccination
In preclinical trials different doses and vaccination sche-
dules are investigated with variable results however,
there is lack of consensus on these issues. Ahmad et al.
have shown that the a DNA vaccine encoding human
PSA significantly delayed the appearance of tumours
and resulted in prolonged survival of the animals [50].
Additionally, a four-dose vaccination regimen provided
optimal immunological effects and co-administration of
synthetic CpG enhanced the tumour protective
responses [50]. Furthermore, these immune responses
were tumour specific and were transferable in adoptive
T cell transfer experiments [50]. A DNA vaccination has
the potential to break tolerance to self antigen
[34,48,51]. A PSCA DNA vaccine when delivered by i.m.
EP [51] or orally administered bacteria, [52] resulted in
induction of anti-tumour immune responses against
PSCA expressing subcutaneous tumours and metastatic
deposits. There was activation of Th-1 type immunity
against PSCA, indicating the breaking of tolerance to a
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cific and was transferable by adoptive transfer of
splenocytes [51].
PSMA is present in both secretary form and in pros-
tate cells. Mincheff et al. [53] evaluated two plasmid
DNA vaccines, encoding either PSMA products that are
retained in the cytosol and degraded in the proteasome
(tVacs; hPSMAt), or secreted proteins (sVacs; hPSMAs)
for stimulation of cytotoxic cell or antibody responses.
They observed that immunisation with both vectors led
to generation of cell cytotoxicity, provided GM-CSF was
administered with the vaccine. Spleen cells from animals
immunised with hPSMAt demonstrated stronger cyto-
toxicity to the target cells. Interestingly, priming with a
vector that encoded a xenogeneic protein (hPSMAt;
‘xenogeneic’ construct) and boosting with a vector that
encoded an autologous protein (rPSMAt; ‘autologous’
construct) gave the best protection against tumour chal-
lenge. Immunisation with tVacs did not lead to forma-
tion of antibodies to the target protein, while
immunisation with sVacs or with the protein did (mixed
Th1-Th2 isotype). But, priming with tVacs and boosting
with protein also resulted in the antibodies from the
cytotoxic Th1 isotype. Hence, the best strategy to obtain
a strong cellular cytotoxic response seems to be gene-
based vaccinations with tVacs, priming with the ‘xeno-
geneic’ and boosting with the ‘autologous’ constructs.
While DNA vaccine injections, either i.m. or i.d., have
been used successfully in many trials, it is still to estab-
lish which route is better. To enhance the efficacy of
DNA vaccine against PCa, Roos et al. [54] have demon-
strated that i.d. DNA vaccination, followed by two sets
of electrical pulses of different length and voltage, can
effectively induce PSA-specific T cells response. Ahmad
et al. have reported successful DNA vaccination follow-
ing i.m. injection coupled with EP. [50,51] These studies
indicate that EP significantly enhances transfection and
hence immune activation.
Clinical trials
Preclinical studies provided encouraging evidence of
enhanced immune responses and tumour protection by
DNA vaccine in animal models of PCa. The success
achieved in these studies resulted in exploration of appli-
cation of DNA vaccine in PCa patients. To our know-
ledge, no naked DNA vaccine has been used in a
randomised clinical trial to date [55]. However, DNA
vaccines have been used in phase I/II clinical trials in-
cluding patients with PCa (Table 1). Some of these clin-
ical trials are discussed below.
In a phase I trial, Pavlenko et al. [15] investigated the
feasibility, safety and immunogenicity of a DNA vaccine
(pVAX/PSA) in patients with CRPC. Cytokines, GM-
CSF and IL-2, were also used as vaccine adjuvants. Theresults of this trial demonstrated that DNA vaccination
with a PSA-coding plasmid vector, given with GM-CSF
and IL-2, is safe and can induce cellular and humoural
immune responses against PSA. However, a dose–
response was observed with regard to induction of a
PSA-specific immune response. Interestingly, in this
trial, two patients that developed cellular immune re-
sponse to PSA exhibited stabilisation of disease. While
only one of six that did not develop PSA-reactivity
showed clinical stabilisation.
Mincheff et al. [14] performed phase I/II trials to deter-
mine the safety of the PSMA vaccine after repeated i.d.
injections. Twenty-six patients with PCa were entered into
this toxicity-dose escalation study. Immunisations were
performed i.d. at weekly intervals. Doses of DNA between
100 and 800 μg and of recombinant virus at 5×108 PFUs
per application were used. They observed no immediate
or long-term side effects following immunisations. All
patients who received initial inoculation with the viral vec-
tor followed by PSMA plasmid boosts showed the devel-
opment of a delayed-type hypersensitivity reaction after
the PSMA plasmid injection. In contrast, to the patients
who received a PSMA plasmid and CD86 plasmid, only
50% showed signs of successful immunisation. Of the
patients who received PSMA plasmid and soluble GM-
CSF, 67% were immunised. However, all patients who
received the PSMA/CD86 plasmid and sGM-CSF became
immunised. The patients who did not immunise during
the first round were later successfully immunised after a
boost with the viral vector. Further to this study, Todorova
et al. [58] characterised the humoural immune response
against PSMA in PCa patients. They demonstrated that
PSMA is a target for humoural immune response induced
by gene-based PSMA vaccination. It is also proposed that
detection of anti-PSMA antibodies by immunoblot ana-
lysis and by indirect immunofluorescence could be used
to monitor the vaccination effects. These results were
quite encouraging, proving evidence of immune activation
with different vaccination regimens. However, the hetero-
geneity of the medical status and the presence of con-
comitant hormone therapy do not permit unequivocal
interpretation of the data with respect to the effectiveness
of the therapy. However, several responders, as evidenced
by a change in the local disease, distant metastases, and
PSA levels, were identified in this cohort.
Low et al. [56] evaluated the use of EP to deliver a
novel DNA vaccine (p.DOM-PSMA(27)). This vaccine
encodes a domain of fragment C of tetanus toxin to in-
duce CD4+ T cell help, fused to a tumour-derived epi-
tope from PSMA for use in HLA-A2+ patients with
recurrent PCa. In this open label phase I/II, two-arm,
dose escalation trial, the DNA vaccine was delivered ei-
ther by i.m injection or by i.m. injection followed by EP.
Three vaccinations were given at 0, 4, and 8 weeks, with
Table 1 Summary of prostate cancer DNA vaccination clinical trials









Immunological responses Adverse effects PSA response
[14] Extracellular human PSMA & CD86
into separate expression vectors
(PSMA & CD86 ), and into a
combined plasmid (PSMA/CD86)
26 Phase I/II i.d. - All patients who received initial
inoculation with viral vector followed
by PSMA plasmid boosts showed
immunisation. In contrast, with PSMA
and CD86 plasmids, only 50% were
immunised.
- -
+ Expression cassette from PSMA
plasmid into a replication deficient
adenoviral expression vector
- Of the patients who received PSMA
& GM-CSF, 67% were immunised.
However, PSMA/CD86 & GM-CSF
vaccination immunised all recipients.
[15] Plasmid vector expressing PSA
& GM-CSF/IL-2
9 CRPC Phase I i.m, i.d. PSA-specific cellular immune response
(measured by IFN- γ & anti-PSA IgG
levels) were detected in highest
dose cohort of patients.
- Systemic effects; running
nose, fatigue, myalgia, chills
and fever (n = 6).
- Drop in PSA (n=3).
- At the injection site; erythema,
swelling, induration, itching,
pain, urticaria (n = 7).
- Increase in PSA (n= 5).
[56] Vaccine encoding a domain of
fragment C of tetanus toxin
fused to a tumour-derived
epitope from PSMA
5 patients / dose
level
Phase I/II, i.m. or
i.m. + EP
Delivery of DNA+EP at all five
vaccinations resulted in activation
of humoral immunity.
- Mild pain at injection site. -
Recurrent PCa - EP did not add toxicity.




Phase I/IIa i.d. - Three of 22 patients developed
PAP-specific IFN-γ secreting CD8+
T-cells. While 9 (41%) patients
developed PAP-specific CD4+
and/or CD8+ T-cell proliferation.
No significant
adverse events
PSA doubling time increased
from a median 6.5 months
per treatment to 8.5 months
on-treatment & 9.3 months
in one year post treatment.
- Antibody responses to PAP were
not detected.
PSMA Prostate Specific Membrane Antigen, CD86 Cluster of Differentiation 86, i.d Intradermal, i.m Intramuscular, PSA Prostate Specific Antigen, GM-CSF Granulocyte-macrophage colony-stimulating factor, IL2 Interleukin
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two dose cohorts, EP did not appear to add toxicity to the
vaccination apart from brief and acceptable pain at injec-
tion site. They also observed highest level of humoural
responses with DNA+EP strategy and these responses per-
sisted to 18 months of follow-up. These data favour EP as
a potent method for stimulating humoural responses
induced by DNA vaccination in humans.
McNeel et al. [57] conducted a phase I/IIa trial with a
DNA vaccine encoding human PAP in patients with
stage D0 PCa. Twenty-two patients were treated in a
dose-escalation trial with 100 μg, 500 μg, or 1,500 μg
plasmid DNA, co-administered i.d. with 200 μg GMC-SF
as a vaccine adjuvant, six times at 14-day intervals. All
of these patients were observed for one year after the
treatment. They did not observe any significant adverse
events. Three of 22 patients developed PAP-specific
IFN-γ secreting CD8+ T-cells immediately after the
treatment course. While nine (41%) out of 22 patients,
developed PAP-specific CD4+ and/or CD8+ T-cell pro-
liferation. However, no humoural response (antibodies
against PAP) was detected. Overall, the PSA doubling
time was observed to increase from a median 6.5
months pre-treatment to 8.5 months on-treatment (P =
0.033), and 9.3 months in the 1-year post-treatment
period (P = 0.054). This study provided 12 months fol-
low up data and demonstrated that the DNA vaccine is
safe, elicits an antigen-specific T-cell response, and may
be associated with an increased PSA doubling time.
Conclusions and future directions
DNA vaccination for PCa is at a crucial developmental
stage. The ultimate goal of any given immunotherapy in-
cluding DNA vaccination is eradication of each and
every cancer cell from the patient. However, this goal
may be hard to achieve. DNA vaccination is a step for-
ward in achieving immune eradication of PCa. Induction
of tumour-specific T cell activation has been demon-
strated with PCa DNA vaccination in both preclinical
and clinical trials. However, in clinical settings, limited
success has been seen in terms of tumour regression and
survival. This vaccine failure may be attributed to several
potential tumour escape mechanisms such as defects in
antigen presentation, production of immunosuppressive
substances, T cell dysfunction, and the presence of regu-
latory T cells [59-61]. Additionally, there is paucity in
the literature of advanced clinical trials to evaluate the
role of DNA vaccination in PCa. Furthermore, in the
available trials there is currently a lack of long-term fol-
low up. Ideally, the availability of data from randomised
clinical trials featuring robust end points such as bio-
chemical response, progression free and overall survival
will provide categorical evidence for DNA vaccination’s
potential.In order to provoke an immune response, a tumour
vaccine should not only maximise antigen-specific sig-
nals, but should also provide the necessary “co-
stimulatory” environment. One approach is to include
lymphokines (GM-CSF, IL-12, IL-15) or include tumour
cell expression of membrane bound molecules (CD80,
CD86) [62]. Furthermore, doses and schedules need op-
timisation; however it is clear that the immune
responses depend on a primary vaccination followed by
booster vaccination(s). Some studies have suggested that
the best strategy for achieving an intense immune re-
sponse can be priming with naked DNA followed by
boosting with a viral vector [14,63]. The use of viral vec-
tors can enhance the immunogenicity of the vaccine due
to the adjuvant properties of some of the viral products.
However, naked DNA immunisation offers several po-
tential advantages over viral mediated transduction.
Among these are the inexpensive production and the in-
herent safety of plasmid vectors, as well as the lack of
immune responses against the carrier [63].
Although the current evidence suggest that the DNA
vaccines can induce immune activation resulting in PCa
control, certain areas still need to be explored such as
selecting the ideal antigen, identifying suitable stages of
PCa for vaccine therapy, optimum dosage/schedule and
adjuvant agents. Evidence suggests that it is unlikely for
a single therapy to achieve the goal of curing PCa espe-
cially patients with CRPC. However, better understand-
ing of immunobiology of PCa will lead to pathways for
development of novel therapies. The perceived difficulty
in translating the effectiveness of DNA vaccination from
small animals to human subjects appears to have been
overcome by use of EP [42]. Current data are from early
stage studies and further research in this field is essential
to determine the place of DNA vaccination as an adju-
vant to surgery, radiotherapy and chemotherapy.
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